Hancock Jaffe Laboratories Inc’s (HJLI) Lock-Up Period To End on November 27th

Hancock Jaffe Laboratories’ (NASDAQ:HJLI) lock-up period is set to end on Tuesday, November 27th. Hancock Jaffe Laboratories had issued 1,500,000 shares in its IPO on May 31st. The total size of the offering was $7,500,000 based on an initial share price of $5.00. After the expiration of Hancock Jaffe Laboratories’ lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

HJLI stock opened at $1.90 on Friday. Hancock Jaffe Laboratories has a 12 month low of $1.64 and a 12 month high of $5.64.

An institutional investor recently bought a new position in Hancock Jaffe Laboratories stock. Vanguard Group Inc. acquired a new stake in Hancock Jaffe Laboratories Inc (NASDAQ:HJLI) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 52,720 shares of the company’s stock, valued at approximately $141,000. Vanguard Group Inc. owned 0.45% of Hancock Jaffe Laboratories at the end of the most recent quarter. Institutional investors and hedge funds own 0.44% of the company’s stock.

WARNING: This piece of content was originally posted by WKRB News and is the sole property of of WKRB News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.wkrb13.com/2018/11/24/hancock-jaffe-laboratories-incs-hjli-lock-up-period-to-end-on-november-27th.html.

Hancock Jaffe Laboratories Company Profile

Hancock Jaffe Laboratories, Inc, a development stage medical device company, develops and sells biological tissue solutions to treat patients with coronary, vascular, end stage renal, and peripheral arterial diseases in the United States and Europe. The company develops and manufactures implantable cardiovascular bioprosthetic devices for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease.

Featured Article: Reverse Stock Split

Receive News & Ratings for Hancock Jaffe Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hancock Jaffe Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply